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The development of the ﬁeld of materials science, the ability to perform multidisciplinary scientiﬁc work, and the need for novel
administration technologies that maximize therapeutic eﬀects and minimize adverse reactions to readily available drugs have led
to the development of delivery systems based on microencapsulation, which has taken one step closer to the target of personalized
medicine. Drug delivery systems based on polymeric microparticles are generating a strong impact on preclinical and clinical drug
development and have reached a broad development in diﬀerent ﬁelds supporting a critical role in the near future of medical
practice. This paper presents the foundations of polymeric microparticles based on their formulation, mechanisms of drug release
and some of their innovative therapeutic strategies to board multiple diseases.
1.Introduction
The discovery and development of new drugs for the treat
ment of diseases is a lengthy and costly process [1]. The drug
development typically requires about 14 years, and studies
demonstratedthatbytheyear2013thecosttoreachphaseIII
ofclinicaltrialswillbearound$1.9billion[2].Moreover,the
number of drug approvals is minimal, reaching less than 32
new molecular entities per year last decade (NME) [3]. The
long time required to develop a new drug application and
its high costs illustrate the need to develop new therapeutic
strategies, which improve the eﬀectiveness of available drugs.
Figure 1 shows a scheme of the diﬀerent stages of drug
development required by the Food and Drug Administration
(FDA) from discovery of an NME until its marketing.
The conventional administration of drugs (i.e., tablets,
capsules, and injections), and the limited solubility of the
drugs often require high doses in order to reach enough con-
centrations of drug at its site of action to achieve an appro-
priate therapeutic eﬀect [4]. In other cases, the application
of some therapeutic protocols requires the administration
of repeated doses to maintain an adequate concentration of
drug in the bloodstream and provide therapeutic action for
long periods of time [5]. The high blood concentrations of
drugs and the administration of multiple doses can generate
signiﬁcative ﬂuctuations of the drug in the bloodstream,
which can reach the toxicological parameters, and generate
adverse reactions for the patients. All this drawbacks have
lead to develop new therapeutic strategies more eﬀective and
with fewer side eﬀects for patients.
The advancement of materials science and pharmaceuti-
cal technology has allowed the creation of several strategies
f o rd r u gd e l i v e r ys u c ha so s m o t i cp u m p s[ 6, 7], liposomes
[8, 9], hydrogels [10–12], and polymeric microparticles [13,
14]. The main goals of those drug delivery devices are the
generation of a sustained release of drug over time, a reduced
number of doses required to the treatment of diseases, and
the protection of the drugs from inactivation before reaching
the target tissue.
The polymeric microparticles (p-MPs) as a drug delivery
strategyhaveadvantagesoverothersystemssincetheydonot
require surgical procedures for their application or removal
from the body like the osmotic pumps. Furthermore, the
p-MPs have exhibited a better stability in the biologi-
cal environment than liposomes, and their highly repro-
ducibleformulationmethodsprovidesupporttoencapsulate
hydrophilic and hydrophobic drugs, which gives them a wide
range of therapeutic applications.2 Journal of Biomedicine and Biotechnology
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Figure 1: Schematic description of the stages required by the Food and Drug Administration (FDA) to reach the commercialization of a new
drug application (NDA).
On the other hand, the release of drugs from p-MPs
shows several beneﬁts compared with the conventional drug
administration methods, which include their ability to mod-
ulate the rate of drugs release for a long time periods and
their capacity to reduce the drug toxicity.
The extensive beneﬁts of administration of encapsulated
drugs into p-MPs serves as the foundation for many fu-
ure medical endeavors. This paper provides an overview
of the basics of polymeric microparticles based on their
formulation, their mechanisms of drug delivery, and their
applications in the treatment of diseases.
2.Polymers
The use of biodegradable and biocompatible polymers has
generated signiﬁcant advances in modern medicine because
ithasimpacteddiﬀerentﬁeldsofbiomedicine,whichinclude
tissue engineering and diagnostic and therapeutic strategies
[15, 16].
The p-MPs, as drug delivery systems, have been devel-
oped using diﬀerent natural and synthetic polymers [17].
The natural polymers include chitosan [18], alginate [19],
dextran[20],gelatin[21],andalbumin[22],andthesynthetic
polymers comprise to poly(lactide-co-glycolide) (PLGA)
[23], (3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV)
[24], poly(sebacic anhydride) [25], poly(ε-caprolac-tone),
among others [26].
During the last years, the advances in materials sciences
have generated diﬀerent polymers tailored for drug-conju-
gated, which include smart response that supported the
development of novel drug delivery systems [27]. Recently,
the use of thermoresponsive (i.e., NIPAAm and CMCTS-
g-PDEA) [28, 29] and pH-responsive (i.e., Eudragit L100,
Eudragit S and AQOAT AS-MG) [30, 31]p o l y m e r si n
the formulation of p-MPs was described, which promises
improved approaches to the delivery of drugs.
3. MicroencapsulationMethods
Understanding the physicochemical properties of drugs is
essential before determining the appropriate method for
the synthesis of the p-MPs because the wide range of
pharmaceutical agents such as peptide, proteins, nucleic
acids, antibiotics, and chemotherapeutics, have distinctive
solubility and stability at diﬀerent conditions (i.e., temper-
ature, pH, and organic solvents) [32, 33]. On the other hand,
the fundamental properties of the polymers for the devel-
opment of p-MPs involve their solubility and stability,
their biodegradability and biocompatibility [34], and their
physical (i.e., crystallinity and glass transition temperature)
and mechanical properties (i.e., strength, elongation, and
Young’s modulus) [35].
The microemulsion methods provided a highly repro-
ducible platform to formulate p-MPs with a uniform size
and predictable inner structure, which can be determinated
by the use of single- or double-emulsion process. The
single-emulsion method consists in an oil/water (O/W) or
water/oil (W/O) emulsion that generates solid spherical
shape microparticles, with a polymeric inner core, which
is favorable to encapsulate hydrophobic drugs [36]. On the
other hand, the proteins and other hydrophilic drugs are
usually encapsulated using the water/oil/water (W/O/W)
double-emulsion method, because it generates core-shell
microparticles characterized by hydrophilic pockets [37].
Figure 2, presents a scheme of the morphology of p-MPs,
formulated by the single- and double-emulsion-evaporation
method. Studies about the conditions of preparation of
p-MPs have shown that high concentrations of polymers
generate an increase of the particles size and a decrease-
loading yield. This phenomenon may be attributed to the
increment in the viscosity of the polymeric phase that emul-
siﬁed to drug [38]. In addition, other studies have described
that the intensity with which it generates the emulsion
aﬀects its internal conformation of microparticles. Mao et al.
(2007) showed by transmission electron microscopy that a
high intensity of emulsion reduced signiﬁcantly the internal
porosity of p-MPs [39].
Despite the high loading eﬃciency that supports the
conventional emulsion methods, recently, innovative pro-
cedures based on double-emulsion method such as the
solid/oil/water (S/O/W), the solid/oil/oil (S/O/O), and the
water/oil/oil (W/O/O) methods have been described, which
allows to maintain their complete structural and functional
integrity of proteins after the microencapsulation process
[40].
Another method to synthesize polymeric micro- and
nanoparticles is through microﬂuidic technology [41–43].
This technique generates droplets or particles in a device (T-
junction) supplied with the polymers and drugs dissolved
in immiscible solutions, followed by the solidiﬁcation of the
droplets by means of polymerization or solvent evaporation
[44]. The main advantage of microﬂuidics is to obtain large
volumes of particles, which have a highly uniform andJournal of Biomedicine and Biotechnology 3
Stabilizing agent
Hydrophilic
drug
Hydrophilic
drug
Polymer
Core-shell
Microparticle Microparticle
Polymeric
Figure 2: Scheme of the morphology of polymeric microparticles prepared by the single- and double-emulsion method and their internal
distribution of drugs with diﬀerent physicochemical properties.
predictable size, which determines their potential use in the
synthesis of multiple polymeric colloids loaded with drugs
and pharmaceutical application [45].
Spray-drying is a method widely used in the pharmaceu-
tical and biotechnology industry for the synthesis of p-MPs
because it allows to produce large quantities of particles with
spherical and amorphous morphology and it can display
roughness or porosity in their surface [46]. In the last years,
spray-freeze-drying methods were able to formulate p-MPs
loaded with poor water-soluble drugs and temperature-
sensitive molecules. In addition, these methods produce
microparticles with controlled size and porosity, making
them particularly attractive to load a wide range of drugs
with biomedical interest [47, 48].
Figure 3 illustrates images of p-MPs prepared in our
laboratory from PLGA and PHBV and characterized using a
confocal laser scanning microscopy, a transmission electron
microscopy, and a scanning electron microscopy.
4. Mechanisms of Drug Release
The release of drugs from p-MPs arises as a consequence
of the degradation and/or erosion of the polymeric device
[49]. Therefore, the knowledge about the chemical nature
of polymers is essential to understand the mechanism of
release. In the cases when degradation of polymeric matrix
occurs, the drug diﬀuses through the channels generated by
the breaking of the polymer chains without loss of volume
in the particle. In contrast, when the polymeric carrier
undergoes erosion, together with the polymer mass loss the
drug is released. In this case, there is a decrease in volume of
polymeric matrix according to the drug release [50–52].
Studieshavedemonstratedthattherateofdegradationof
polyesters such as PLGA or PHBV is inversely proportional
to the molecular weight of the polymers. Furthermore, the
degradation time of PLGA (copolymer) depends on the
ratio of its monomers, poly(lactic acid) and poly(glycolic
acid), such that polymers containing a higher concentration
of poly (lactic acid) exhibited a slower degradation [49].
Others studies have showed that high temperatures and low
pH condition increase the degradation of polymers with
a subsequent increment of the release rate of drug encap-
sulated into polymeric microparticles [53, 54].
5. Therapeutic StrategiesBased on
Polymeric Microparticles
The p-MPs formulations have unique properties in terms of
particle size, shape, inner structure, porosity, drug loading,
encapsulation eﬃciency, and proﬁle of release [55, 56].
Therefore, the selection of an appropriate route of adminis-
tration of p-MPs (i.e., intramuscular, intraperitoneal, intra-
articular,andintrapulmonary)isacriticalelementtoachieve
an expected pharmacological action.
5.1. Oncologic Disease. Cancer is one of the most signiﬁcant
causes of death worldwide, and the gliomas are the leading
brain tumors of the nervous system in adults. It has been
describedthatgliomashaveanexceptionalabilitytoinﬁltrate
to healthy tissue, which makes them extremely diﬃcult to
be treated [57]. Chemotherapy is one of the most widely
used strategies to treat cancer. However, its low speciﬁcity
and high toxicity generate negative eﬀects for patients that
may cause serious complications, aﬀecting in some cases
other healthy physiological systems [58–60]. Therefore, the
administration of chemotherapeutic agents loaded in poly-
meric microparticles provides a secure platform to achieve a
sustainedrelease in the cancerous tissue, decreasing the use
of high doses of drugs and their potential harmful eﬀects
[61, 62].
Recently,Y.H.Zhangetal.(2010)describedastudyusing
orthotopic implantation of C6 glial cells in a rat brain to
evaluate the activity of polymeric microparticles loaded with4 Journal of Biomedicine and Biotechnology
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Figure 3: Polymeric microparticles formulated by single- (a) and double- (b, c, and d) emulsion method. Images obtained through confocal
laserscanningmicroscopyof(a)FITC-loadedpoly(lactide-co-glycolide)(PLGA)microparticles(MPs)(green),(b)NBD-cholesterol(green),
andTexas-Red(red)loadedPLGAmicroparticles.(c)Transmissionelectronmicroscopy(TEM)ofceftiofur-loadedpoly(3-hydroxybutyrate-
co-3-hydroxyvalerate) (PHBV) microparticles; (d) scanning electron microscopy (SEM) of ﬂorfenicol-loaded PHBV microparticles.
temozolomide (tm-MPs) injected into the tumor area. The
results showed a better survival to the group that received
tm-MPs (46 days) than the control group treated orally
with nonencapsulated temozolomide (27 days). Moreover,
through magnetic resonance imaging (MRI), they found
that the group treated with tm-MPs showed the greatest
reduction of the tumor size and decrease of the proliferative
activity of cells. Furthermore, the cells also presented an
increased rate of apoptosis, suggesting that the encapsulation
of temozolomide in p-MPs enhanced its chemotherapeutic
eﬀect [63]. Other in vitro studies, using similar strategies
for the localized release of paclitaxel and cisplatin from
polymeric microparticles, also exhibited greater eﬃcacy than
the administration of nonencapsulated drug [64, 65].
In the last few decades, the use of intraperitoneal chemo-
therapy has showed high eﬃcacy in the treatment of
peritoneal and ovarian cancer, which has allowed enhancing
the survival of many patients [66–68]. However, the use of
intraperitoneal therapy also has presented some limitations
that increase the risk of infection due to the use of catheters
for the administration of drugs [69]. Other drawbacks have
been associated with the use of chemotherapeutic agents that
present hematologic and hepatic toxicity such as cisplatin,
melphalan, and etoposide [70–73] and the slow absorption
oflesstoxicdrugs,suchaspaclitaxel,mitoxantrone,anddox-
orubicin, which do not have a deep tumor penetration [74–
77]. Studies have shown that intraperitoneal treatment of
ovarian cancer in mice model with paclitaxel-loaded p-MPs
has overcome the limitations of free paclitaxel therapy. The
administrationofpaclitaxel-loadedpolymericmicroparticles
exhibited biphasic release kinetics, characterized by a rapid
initial release that was suﬃcient to prevent tumor prolifer-
ation and a second phase of sustained release that allowed
for the gradual eradication of the tumor [78]. Furthermore,Journal of Biomedicine and Biotechnology 5
intraperitoneal chemotherapy based on microparticles has
reduced the removal of the drug from the peritoneal cavity,
leading to slow systemic absorption and maintaining the
therapeutic concentrations for longer periods of time (10
to 45 times) in the intraperitoneal region, which generated
a signiﬁcant increase of survival groups treated with p-MPs
[79].
5.2. Cardiac Disease. Cardiac dysfunction followed by acute
myocardial infarction is one of the leading causes of death
worldwide [80, 81]. The excessive inﬂammatory response
after the ischemic heart disease generates a chronic elevation
of inﬂammatory cytokines and reactive oxygen species,
which may lead to cardiac dysfunction [82–84]. Recently,
the release of anti-inﬂammatory drugs from polymeric
microparticles administrated via intracardiac injection has
shown promising results to treat the myocardial infarction
and other inﬂammatory diseases, due to blocking the activa-
tion of macrophages and thereby reducing the apoptosis or
necrosis of cardiomyocytes [85, 86].
Recent therapeutic approaches to prevent the devel-
opment of cardiac failure after myocardial infarct include
the direct administration of proangiogenic growth factors
[87] and stem cell therapy [88, 89]. However, despite the
promising results obtained in animal models and clinical
trials [90, 91], some studies have shown limited eﬀectiveness
with the administration of growth factors because the native
and recombinant proteins exhibited a short half-life and
instability [92, 93]. In order to improve those drawbacks,
Formiga et al. (2010) have described the synthesis of PLGA
microparticles loaded with the cytokine VEGF165,ap r o a n -
giogenic growth factor, and evaluated their vasculogenic
eﬀect in a rat model of myocardial infarction. The results
obtained showed an excellent angiogenic and arteriogenic
eﬀect induced by the sustained release of the cytokine
VEGF165 from the polymeric microparticles [94].
5.3. Immunological Response. Studies under preclinical drug
development based on p-MPs have been focusing on the
development of strategies that reduce organ rejection and
prevent autoimmune diseases. Wu and Horuzsko (2009)
proposedamethodforimprovingimmunetolerancebyden-
dritic cell receptor stimulation with ILTs (immunoglobulin-
like transcripts). Dual coating the surface of p-MPs with
the HLA-G1-peptide, an ILTS receptor ligand, and a mon-
oclonal antibody against the CD11c marker improved the
modulation of dendritic cells. This system could provide a
method to regulate speciﬁc immune responses that occur
during transplantation, autoimmunity, and allergy [95].
New approaches in the vaccine ﬁeld include poly-
meric microparticles loaded with antigens against bacterial
pathogens such as Vibrio cholerae [96], Pseudomonas aerug-
inosa [97], and Bordetella pertussis [98], providing a potent
and long-time immune response.
On the other hand, the gene delivery from p-MPs
provides a highly attractive strategy because it can generate
the in situ expression of target antigens and preserve the
native structure of proteins [99]. In addition, the p-MPs
can codeliver DNA and adjuvants generating an improved
immune response [100, 101]. The current strategies have
used polymers with cationic charge such polyethyleneimine
to increase the loading and encapsulation eﬃciency of
DNA inside particles [102]. Despite great advances in the
development of DNA vaccines and their potential against
several diseases, the biggest challenge is to establish the safety
of using DNA vaccines in human medicine [103].
5.4. Diabetes. In the last decade, there was a notable increase
of diabetes around the world [104]. The islet transplantation
to patients with severe diabetes has improved their quality
of life [105, 106]. However, these transplanted cells are
highly susceptible to oxidative stress, which may decrease
their proliferative capacity and lead to cellular death [107,
108]. The antioxidant eﬀect of vitamin D3-loaded polymeric
microparticles was evaluated in cultured islets isolated from
adult rat. The results exhibited a signiﬁcantly increased
insulin production compared to the untreated control
groups [109].
Other studies have described novel strategies for the oral
and parenteral administration of insulin-loaded PLGA and
poly(N-vinylcaprolactam-co-methacrylic acid) microparti-
cles [110]. The particles were synthesized using ﬂow focus-
ing, double-emulsion-solvent evaporation method, and the
free radical polymerization procedure [111, 112].
Recently, Technosphere/Insulin, an inhalable formula-
tion under development by MannKind Corporation (Valen-
cia, CA), have initiated the Phase III in both Europe and
the US. The Technosphere technology allows to administer
insulin via pulmonary and oﬀers several competitive advan-
tages over other pulmonary drug delivery systems. Recent
studies have been conducted to analyze the lung deposition
and clearance after administration. Their ﬁndings showed a
uniform distribution throughout the lungs and absorption
of insulin into the systemic circulation. Based on the results
of clinical trials and on published reports, Technosphere is
better than other inhaled insulin platforms [113].
6. Prospects
Multidisciplinary work in the 21st century of physicians,
biomaterials and chemical engineers, and researchers in
biotechnology has allowed creating new frontiers to the
landscape of pharmaceuticals.
The incorporation of polymeric microparticles as car-
riers of drugs in medical practice improves the disadvan-
tages generated by elevated plasma levels short-term and
adverse reactions caused by the traditional pharmaceutical
formulation. It also creates novel strategies for localized
and sustained release sites with low vascular permeability.
Moreover, the wide range of biomaterials with diﬀerent
physicochemical properties allow the creation of smart sys-
tems for drug delivery, which promote an optimal response
and long-term eﬃcacy in the treatments of diﬀerent diseases.
The development of polymeric microparticles, as drug
delivery systems, has set the foundation for the emerging
and signiﬁcant role of nanomedicine based on polymeric6 Journal of Biomedicine and Biotechnology
nanoparticles as carriers of drugs [114–116]. We are opti-
mistic about the marketing in the near future of innovative
technology based on polymeric microparticles because it
may generate a new era in modern medicine.
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